Canada Markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
9.84-0.26 (-2.57%)
At close: 04:00PM EST
9.95 +0.11 (+1.12%)
After hours: 07:58PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close10.10
Open10.06
Bid9.88 x 1100
Ask9.95 x 800
Day's Range9.85 - 10.25
52 Week Range2.81 - 10.72
Volume2,202,979
Avg. Volume1,852,831
Market Cap141.03M
Beta (5Y Monthly)1.54
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
All
News
  • GlobeNewswire

    BriaCell Adds Mary Crowley Cancer Research Center as a Clinical Trial Site for its Phase I/IIa Breast Cancer Study

    NEW YORK and VANCOUVER, British Columbia, Nov. 18, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that Mary Crowley Cancer Research center in Dallas, Texas is now actively screening and enrolling advanced breast cancer patients in the Phase I/IIa combination study of BriaCell’s lead candidate

  • GlobeNewswire

    BriaCell Announces Update on Previously Announced Securities Buyback Program and Participation at Upcoming Conferences

    BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, today announces the following updates: Pursuant to the securities buyback program announced Sept. 9, 2021, BriaCell has repurchased 202,425 common shares (the “Common Shares”) and 70,246 publicly t

  • GlobeNewswire

    BriaCell Adds Pioneering Immunologist and Cancer Immunotherapy Expert, Suzanne Ostrand-Rosenberg, Ph.D., to its Scientific Advisory Board

    NEW YORK and VANCOUVER, British Columbia, Nov. 05, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces the addition of Suzanne Ostrand-Rosenberg, Ph.D. to its Scientific Advisory Board. Dr. Ostrand-Rosenberg has more than 40 years of experience leading investigations focused on the immune system’s